Atripla Placebo

DRUG3 trials

Sponsors

Gilead Sciences, ViiV Healthcare, University of Alberta

Conditions

HIVHIV InfectionsHIV-1-infectionInfection, Human Immunodeficiency Virus I

Phase 3

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT01095796

Gilead SciencesHIV, HIV Infections

Start: 2010-03-31End: 2014-09-30Updated: 2015-11-11

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

CompletedNCT01263015

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2011-02-01End: 2015-12-03Updated: 2018-04-04

Phase 4

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

TerminatedNCT03532425

University of AlbertaHIV-1-infection

Start: 2018-10-29End: 2020-09-03Updated: 2022-12-14

Related Papers

Safety and Efficacy of DTG Plus ABC/3TC for Treatment-Naive Patients with HIV

MD Conference Express2014-11-01

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

New England Journal of Medicine2013-11-06862 citations

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

2012-06-01331 citations